News

Targeting HIF-2alpha protein may be therapeutic approach for PAH

Findings of a new study into pericytes — cells with multiple functions including immune cell regulation — suggest that targeting a protein known as HIF-2alpha, which is involved in the response to low oxygen conditions, or hypoxia, may be a potential therapeutic approach for pulmonary arterial hypertension (PAH). The…

Possible diagnostic biomarkers ID’d for COVID-19 complicated by PH

Researchers have identified two inflammation-related genes — SELE and CCL20 — whose activity could serve as diagnostic biomarkers for the development of pulmonary hypertension (PH) in people with COVID-19. Further, the team also identified molecules that target these biomarkers as possible therapeutic approaches for managing the complication. Overall, the…

Skeletal muscle dysfunction not cause of reduced exercise capacity

Reduced exercise capacity appeared to be a consequence of cardiac and pulmonary changes, but not skeletal muscle alterations, in rat models of pulmonary hypertension (PH), according to recent research. While no functional problems with muscles could be observed despite obvious impairments in exercise capacity, significant cardiopulmonary dysfunction was already present.

Chiesi, Gossamer to advance seralutinib for PAH, other disorders

Chiesi Group has reached an agreement with Gossamer Bio to develop and market seralutinib for certain types of pulmonary hypertension (PH). The agreement seeks to support the therapy’s ongoing testing in pulmonary arterial hypertension (PAH) and to accelerate its development for pulmonary hypertension associated with…

Diet changes may treat pulmonary hypertension, study suggests

A diet poor in two amino acids called glutamine and serine may improve the health of pulmonary blood vessels and reduce the progression of pulmonary hypertension (PH), according to a recent study. Specifically, researchers found that these amino acids are used by cells in blood vessels to produce other…

PM20D1 levels may predict mortality risk in idiopathic PAH

Low levels of PM20D1, a molecule involved in metabolizing lipids, were identified as a risk factor for mortality in people with pulmonary arterial hypertension (PAH), a study reports. As a result, PM20D1, or peptidase M20 domain containing 1, may be a biomarker of disease prognosis, according to scientists. Lipid…

Two genes identified as potential drivers of PAH with HIV infection

Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in people with HIV-1 infection in a bioinformatics study, offering new perspectives to uncover the underlying molecular mechanisms that link HIV infection and PAH. The genes ISG15 and IFI27 are established hub genes involved in the type…